The American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, scheduled for May 29 to June 2, 2026, will feature the unveiling of a clinical research abstract for BAL0891, an anticancer drug being developed by SillaJen.

BAL0891 is currently undergoing Phase 1 clinical trials in the U.S. and South Korea, targeting patients with solid tumors and acute myeloid leukemia (AML). The Phase 1 trial is structured into four sub-trial groups.

These groups include monotherapy for solid tumor patients (Sub-trial 1), combination therapy with immune checkpoint inhibitors (Sub-trial 2), combination therapy with chemotherapy drugs (Sub-trial 3), and monotherapy for AML patients (Sub-trial 4).

At the recent American Association for Cancer Research (AACR) Annual Meeting 2026, two fundamental studies on BAL0891 were presented.

These studies examined BAL0891's effectiveness using patient-derived gastric cancer organoid models and evaluated the synergistic effects of BAL0891 and G-CSF in triple-negative breast cancer models. The research provided valuable insights into the drug's pharmacological mechanisms and potential synergies.

A spokesperson for SillaJen commented that having the BAL0891 research accepted at the prestigious ASCO Annual Meeting marks a significant milestone. It intends to continue sharing the research outcomes through official channels, including academic conferences, as it accumulates more clinical data.

The American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, scheduled for …

SillaJen's Breakthrough Cancer BAL0891 Drug Set for ASCO 2026 Reveal